Iodoazomycin Riboside [l-(5′-iodo-5′- deoxyribofuranosyl)-2-nitroimidazolel, a Hypoxic Cell Marker In Vivo Evaluation in Experimental Tumors
Radiosensitizers labelled with nuclides which emit gamma rays have been proposed to have clinical value in the detection of radioresistant hypoxic cell populations in tumors . Such a diagnostic procedure would be of value for radiation and/or chemotherapy treatment planning in oncology, and could aid the study and treatment of ischemic tissue in the myocardium and in the brain. However, the sensitizers 4-[82Br]-bromomisonidazole (BrMISO)  and l-[2-(2-[131I]iodophenoxy)-ethyl]-2-nitroimidazole (IPENI)  failed to undergo selective uptake in experimental tumor models. In both cases, and especially with IPENI, the test substances were more lipophilic than hypoxic cell markers used previously . Recent efforts with tritiated misonidazole to label hypoxic cell fractions in human tumors have provided clinical data which support the concept that hypoxic cells may be detected by scintigraphic methods .
KeywordsSugar HPLC Ethyl Adenocarcinoma Iodine
Unable to display preview. Download preview PDF.
- 3.Wiebe LI, Jette DC, Chapman JD (1984) Electron-affinic compounds for labelling hypoxic cells: the synthesis and characterization of 1-[2-(2-iodophenoxy)-ethyl]-2-nitroimidazole. Nuklearmedizin 2:63–67Google Scholar
- 5.Chapman JD et al. Unpublished work in progressGoogle Scholar
- 6.Jette DC, Wiebe LI, Lee J, Flanagan RJ, Chapman JD (in press) Iodoazomycin riboside [1- (5′-iodo-5′-deoxyribofuranosyl)-2-nitroimidazole], a hypoxic cell marker. 1. In vitro characterization. Rad ResGoogle Scholar
- 9.Thorndyke C, Meeker BE, Thomas G, Lakey WH, McPhee MS, Chapman JD (1985) The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinoma. J Urol 134Google Scholar